Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
NCT ID: NCT06754553
Last Updated: 2025-01-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2025-02-28
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Reduction of DA frequently leads to a worsening of motor signs (parkinsonism or dyskinesias due to the concomitant increase of levodopa doses) and non-motor signs with the appearance of a DA withdrawal syndrome (DAWS).
Chronic stimulation of the sub-thalamic nuclei may reduce ICD but is restricted to a minority of patients and cases of new-onset ICD symptoms post stimulation have been reported. The benefit of amantadine in pathological gambling is controversial and the efficacy of clozapine has been reported in a few cases but with serious safety limitations. Very recently, naltrexone did not significantly improve ICD.
Thus, an efficacious and safe treatment of ICD in PD remains an unmet need for clinical practice.
Recently, it has been reported that pimavanserin, a selective serotonin 5-HT2A inverse agonist with a satisfactory safety profile without motor side effects, was efficient in improving psychosis, insomnia and day-time sleep in PD.
Pimavanserin, marketed under the tradename NUPLAZID® was approved in 2016 by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
The link between serotonin and ICD has been well established, since the enhancement of 5HT2A receptors stimulation is associated to ICD, since serotonin modulates mesolimbic dopaminergic reward system transmission and given that serotonin neurotransmission is increased during chronic intake of dopamine agonist such as pramipexole which is well-known to induce ICD in PD patients. Thus, there is a large body of evidence suggesting that the decrease of the 5HT2A activity could be efficient in reducing ICD in PD. This further supports the concept of testing the efficacy of pimavanserin (a selective 5HT2A inverse agonist) for treating ICD in PD. Our aim is to conduct a study evaluating the efficacy and safety of pimavanserin on ICD in PD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
NCT03947216
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
NCT03482882
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
NCT01174004
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
NCT04292223
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
NCT06068465
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental: PIMAVANSERIN
In this arm, each patient took orally, once daily 2 tablets of active drug pimavanserin of 17mg each during the 8-weeks treatment period.
Assessment of severity of ICD (impulse control disorders)
Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors
Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
Assessment of quality of life
Parkinson's Disease questionnaire (PDQ-39) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
Assessment of depression
Montgomery-Åsberg Depression Rating Scale (MADRS) administered at day 0 and day 56 (week 8)
Assessment of cognition
Cognitive state of patients by Montreal Cognitive Assessment (MOCA) assessed at day 0
Assessment of severity of Parkinson Disease
Clinical Global Impression Severity scale (CGIS) administered at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
Cardiac monitoring
Electrocardiogram realized at day 0, 28 and 56.
Placebo
In this arm, each patient took orally, once daily, 2 tablets of matching placebo (containing all of the same excipients except for the active compound) during the 8-weeks treatment period.
Assessment of severity of ICD (impulse control disorders)
Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors
Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
Assessment of quality of life
Parkinson's Disease questionnaire (PDQ-39) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
Assessment of depression
Montgomery-Åsberg Depression Rating Scale (MADRS) administered at day 0 and day 56 (week 8)
Assessment of cognition
Cognitive state of patients by Montreal Cognitive Assessment (MOCA) assessed at day 0
Assessment of severity of Parkinson Disease
Clinical Global Impression Severity scale (CGIS) administered at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
Cardiac monitoring
Electrocardiogram realized at day 0, 28 and 56.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Assessment of severity of ICD (impulse control disorders)
Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors
Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
Assessment of quality of life
Parkinson's Disease questionnaire (PDQ-39) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
Assessment of depression
Montgomery-Åsberg Depression Rating Scale (MADRS) administered at day 0 and day 56 (week 8)
Assessment of cognition
Cognitive state of patients by Montreal Cognitive Assessment (MOCA) assessed at day 0
Assessment of severity of Parkinson Disease
Clinical Global Impression Severity scale (CGIS) administered at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
Cardiac monitoring
Electrocardiogram realized at day 0, 28 and 56.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient, man or woman, aged from 35 to 75 years old
* Patient with moderately severe ICD assessed by QUIP-RS (each item being rated 0-16) defined as:
a combined ICD total score (defined as the sum of the 4 ICD sub-scores (pathological gambling + buying + hypersexuality + eating)) superior or equal to 10 or, at least one of the 4 ICD sub-scores in the following range:
"pathological gambling" sub-score from 6 to 12 (included), "buying" sub-score from 8 to 12 (included), "hypersexuality" sub-score from 8 to 12 (included), "eating" sub-score from 7 to 12 (included) (Weintraub et al., 2012). The use of "lower" margins will guarantee that the patient experiences behavioral disturbances severe enough to justify pimavanserin treatment. On the other hand, the use of "upper" margins will guarantee that the patients included in the trial will not suffer from ICD severe enough to question ethically the use of placebo during the 8 weeks of the treatment. Eligibility of patients with QUIP-RS sub-scores above 12 will be assessed upon investigator's request by an adjudication committee composed by independent experts external to the study
* ICD onset after PD onset and after initiation of dopaminergic drugs
* Patient treated by dopaminergic drugs for at least 3 months before randomization in the PIMPARK study
* Patient treated with a stable regimen of levodopa, dopamine agonists, COMT and MAOB inhibitors, amantadine, anticholinergic, antidepressant and benzodiazepine for at least 1 month before the randomization and be willing to remain on the same doses throughout the course of their participation in the trial (Papay et al., 2014)
* Patient with health insurance
* Patient/ guardian / curator who sign the written informed consent for the PIMPARK study
* For women of childbearing potential, use of an effective contraception method for at least 1 month prior to randomization in the PIMPARK study until 8 weeks after the last dose of study drug administration.
* Having participated in the PHRC N 2015 - HUS N°6398 study (PIMPARK study) during the period from 23/10/2020 to 17/06/2024.
* Not objecting, after information, to the reuse of its data from the study PHRC N 2015 - HUS N°6398 for the purposes of this research.
Exclusion Criteria
* Patient who have a known hypersensitivity to the study treatment, based on known allergies to drugs of the same class
* Stroke, uncontrolled serious medical illness, myocardial infarction, congestive heart failure, cardiac function disorders, within 6 months before randomization
* Patient with history of long QT syndrome
* Patient with long QTcB detected with ECG at inclusion visit (\> 450 ms)
* Patient treated with antipsychotic drugs during the last three months before randomization in the PIMPARK study
* Patient treated with concomitant medication leading to torsade de pointes (TdP) without discontinuation ≥ 5 half-lives before randomization (please refer to medications list with known risks of TdP on appendix XVII.5.10 and check website https://crediblemeds.org/index.php/tools/ for the most up-to-date information)
* Patient with hydro-electrolytics troubles, particularly hypokaliemia or hypocalcemia not corrected, at inclusion visit or assessed no later than 8 days before randomization. To be eligible, the patient's electrolyte values should be within the following limits:
3.5 ≤ K+ ≤ 5 mmol/L 135 ≤ Na+ ≤ 145 mmol/L 2,20 ≤ Ca2+ ≤ 2,60 mmol/L
* Patient treated with a strong or moderate CYP3A4 inducer: carbamazepine, rifampicin, phenytoin, modafinil, efavirenz or a strong inhibitor of CYP3A4: azole antifungals, protease inhibitors, macrolids, without discontinuation ≥ 5 half-lives before randomization
* Patient treated with medicinal plants interacting with CYP3A4 without discontinuation ≥ 5 half-lives before randomization (Echinacea (E.pupurea, E.angustifolia and E.pallida), Piperina, Artemisia, St. John's Wort and Ginkgo Patient with Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score \< 20 (to exclude patients likely with dementia) at inclusion visit (Papay et al., 2014).
* Patient suffering from severe depression or marked suicidal thoughts (score \> 3 on the suicidal thoughts item of the MADRS) at inclusion visit (Papay et al., 2014)
* History of DBS within the past year before randomization, or change in stimulation parameters less than one month prior to randomization Hematologic or solid malignancy diagnosis within 5 years prior to randomization.
* Patient suffering from severe renal impairment define as CrCL\<30 mL/min, Cockcroft-Gault at inclusion visit or assessed no later than 8 days before randomization
* Clinically significant hepatic impairment
* Concurrent participation in another research involving a drug or medical device
* Patient with language barriers precluding adequate understanding or co-operation or who, in the opinion of the investigator, should not participate in the trial
* Treatment with an investigational treatment within 30 days prior to randomization
* Woman pregnant, nursing or of childbearing potential age without effective contraception methods or intends to become pregnant.
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NS-PARK Network
UNKNOWN
EUCLID Clinical Trial Platform
OTHER
F-CRIN
UNKNOWN
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Neurologie et Centre d'Investigation Clinique CHRU de Besançon,
Besançon, , France
SERVICE DE NEUROLOGIE Unité Mouvement anormaux Centre expert Parkinson (centre coordinateur interrégional pour la région Sud-Est) Service de neurologie C Hôpitaux Universitaires de Lyon Hôpital Neurologique Pierre Wertheimer
Bron, , France
SERVICE DE NEUROLOGIE Unité Mouvement anormaux Centre expert Parkinson (région Sud-Est) Hôpitaux Universitaires de Clermont-Ferrand Hôpital Gabriel Montpied
Clermont-Ferrand, , France
SERVICE DE NEUROLOGIE Pathologies du mouvement Centre expert Parkinson (région Ile-de-France) Hôpital Henri Mondor
Créteil, , France
SERVICE DE NEUROLOGIE Pathologies du mouvement Centre expert Parkinson (région Sud-Est) CHU de Grenoble Alpes
Grenoble, , France
SERVICE DE NEUROLOGIE Unité Mouvement anormaux Centre expert Parkinson (centre de coordination pour la région Nord-Ouest) Hôpitaux Universitaires de Lille Hôpital Roger Salengro
Lille, , France
SERVICE DE NEUROLOGIE Pathologies du mouvement Centre expert Parkinson (région Sud-Ouest) Hôpitaux Universitaires de Limoges
Limoges, , France
SERVICE DE NEUROLOGIE Unité Mouvement anormaux Centre expert Parkinson (centre de coordination pour la région Sud Méditerranée) Hôpitaux Universitaires de Marseille Hôpital La Timone
Marseille, , France
SERVICE DE NEUROLOGIE Pathologies du mouvement Centre expert Parkinson (centre de coordination pour la région Ouest) Centre d'investigation clinique Hôpitaux Universitaires de Nantes
Nantes, , France
SERVICE DE NEUROLOGIE Centre expert Parkinson (centre de coordination pour la région Ile-de-France) Hôpital de la Pitié-Salpêtrière
Paris, , France
CIC Hôpitaux Universitaires de Poitiers
Poitiers, , France
Service de neurologie, Hôpitaux Universitaires de REIMS
Reims, , France
SERVICE DE NEUROLOGIE Pathologies du mouvement Centre expert Parkinson (région Ouest) Hôpitaux Universitaires de Rennes-Hôpital Pontchaillou
Rennes, , France
SERVICE DE NEUROLOGIE Pathologies du mouvement Centre expert Parkinson (région Nord-Ouest) Hôpitaux Universitaires de Rouen Hôpital Charles Nicolle
Rouen, , France
SERVICE DE NEUROLOGIE Unité Mouvement anormaux Centre expert Parkinson (centre de coordination pour la région Est) Hôpitaux Universitaires de Strasbourg Hôpital de Hautepierre
Strasbourg, , France
SERVICE DE NEUROLOGIE Unité Mouvement anormaux Centre expert Parkinson/Centre d'Investigation Clinique -Hôpital Pierre-Paul Riquet
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9552
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.